Marshall Wace, LLP Rvl Pharmaceuticals PLC Transaction History

Marshall Wace, LLP

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$1.28 - $2.91 $14,464 - $32,883	11,300 New	11,300 $24,000
Q2 2021 Aug 13, 2021	SELL	$2.8 - $3.78 $110,899 - $149,714	-39,607 Reduced 40.6%	57,958 $174,000
Q4 2020 Feb 16, 2021	SELL	$4.12 - $6.29 $783,343 - $1.2 Million	-190,132 Reduced 66.09%	97,565 $402,000
Q3 2020 Nov 16, 2020	BUY	$4.82 - $8.77 $316,620 - $576,092	65,689 Added 29.59%	287,697 $1.56 Million
Q2 2020 Aug 13, 2020	SELL	$2.83 - $6.99 $292,421 - $722,269	-103,329 Reduced 31.76%	222,008 $1.5 Million
Q1 2020 May 15, 2020	BUY	$3.18 - $7.0 $873,670 - $1.92 Million	274,739 Added 542.98%	325,337 $1.03 Million
Q4 2019 Feb 14, 2020	BUY	$3.46 - $7.7 $175,069 - $389,604	50,598 New	50,598 $354,000

92.5K

Ticker RVLP
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 99,150,000
Description
RVL Pharmaceuticals plc, a specialty pharmaceutical company, focuses on the development and commercialization of pharmaceutical products that target markets with underserved patient populations in the ocular and medical aesthetics therapeutic areas in the United States, Argentina, and Hungary. The company is commercializing Upneeq (RVL-1201), an...

Get notified when there are updates to the investment portfolio of Marshall Wace, LLP, based on Form 13F filings with the SEC.

Stay updated on Marshall Wace, LLP with notifications on news.